Shortage of Abatacept (Orencia®) Resolved – update
Update: August 28, 2024.
Bristol Myers Squibb (BMS), the manufacturer of Orencia (abatacept), has announced that the shortage of subcutaneous abatacept will be resolved as of the 30 August 2024.
Starting from 30 August 2024:
- The TGA medicine shortage notification for abatacept 125 mg single dose syringe will no longer be in place.
- The abatacept 125 mg single-dose syringe, BMS, China Stock approved under Section 19A will no longer be available.
- Normal ordering processes for both abatacept pre-filled syringe and ClickJect autoinjector can resume via the DHL online portal.
- Patients may switch back to, or new patients may be initiated on, any of the abatacept presentations as deemed appropriate by the treating physician.
Patients should consult with their healthcare providers for further information.
Discover more...
-
Arthritis Australia launches its first Reconciliation Action Plan
MEDIA RELEASE Arthritis Australia has proudly launched its first Reconciliation Action Plan (RAP), marking a significant milestone in the organisation’s commitment to building stronger relationships...
-
Building the Case for a National Arthritis & Musculoskeletal Research Mission
On March 30 we launched our new report, Evaluation of Preferred Investment Models for Arthritis and Musculoskeletal Research, making a powerful case for a dedicated...
-
New Campaign Urges Shift to Evidence-Based OA Care for World Arthritis Day
New national campaign launches to combat misinformation and empower over 2 million Australians living with OA. In the lead-up to World Arthritis Day (12 October),...
Sign up to Arthritis Insights
Regular updates, news and research findings delivered to your inbox:
